Absci and Memorial Sloan Kettering partner to search for cancer drugs using AI
Briefly

MSK and Absci partner to use generative AI to discover novel cancer therapies, combining expertise in oncology with AI's drug designing capabilities.
MSK's collaboration with Absci signifies a significant step in the realm of life sciences AI, aiming to lead in cancer care and AI integration.
The unique partnership signifies a groundbreaking approach in the industry, focusing on co-development and funding initiatives for drug discovery using AI.
Partnership born from discussions at a healthcare conference highlights the increasing role of AI in advancing medical research and innovation.
Read at ZDNET
[
|
]